Inactive Instrument

Press Releases Novogen Limited Australian S.E.

Equities

AU000000NRT0

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Kazia Therapeutics : Purchase Agreement - Form 6-K	Apr. 19	PU
Kazia Therapeutics : Corporate Presentation	Apr. 11	PU
Kazia Therapeutics : Half Yearly Report - 31 December 2023 - Form 6-K	Mar. 27	PU
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases	Mar. 21	PR
Kazia Therapeutics : EVT801 Progress Update Presentation	Mar. 19	PU
Stocks Making Waves: Insights into Key Developments and Potential VTAK, TBIO, OCEA, ONMD, KZIA	Feb. 27	AQ
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 (Updated)	Feb. 21	AQ
KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS	Jan. 18	PR
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 (Updated)	Dec. 22	AQ
Kazia Therapeutics Announces $2 Million Registered Direct Offering	Dec. 04	AQ
KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY	Nov. 29	PR
KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING	Nov. 21	PR
KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING	Nov. 15	PR
KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA	Nov. 10	PR
KAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMA	Nov. 01	PR
KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY	23-10-23	PR
Kazia announces voluntary delisting from ASX	23-10-11	PR
KAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGS	23-10-05	PR
KAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING	23-09-29	PR
KAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMS	23-01-16	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Novogen Limited Australian S.E.

Equities

AU000000NRT0

Press Releases

Filters